KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Research & Development (2016 - 2026)

Emergent BioSolutions has reported Research & Development over the past 16 years, most recently at $10.5 million for Q1 2026.

  • For Q1 2026, Research & Development fell 30.46% year-over-year to $10.5 million; the TTM value through Mar 2026 reached $48.6 million, down 31.26%, while the annual FY2025 figure was $53.2 million, 24.75% down from the prior year.
  • Research & Development for Q1 2026 was $10.5 million at Emergent BioSolutions, down from $12.1 million in the prior quarter.
  • Over five years, Research & Development peaked at $49.8 million in Q2 2022 and troughed at $9.1 million in Q4 2024.
  • A 5-year average of $25.4 million and a median of $15.3 million in 2023 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: plummeted 69.05% in 2024 and later skyrocketed 32.97% in 2025.
  • Year by year, Research & Development stood at $47.0 million in 2022, then crashed by 37.45% to $29.4 million in 2023, then plummeted by 69.05% to $9.1 million in 2024, then skyrocketed by 32.97% to $12.1 million in 2025, then dropped by 13.22% to $10.5 million in 2026.
  • Business Quant data shows Research & Development for EBS at $10.5 million in Q1 2026, $12.1 million in Q4 2025, and $13.5 million in Q3 2025.